PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.

Biopharma 111

Biopharma Pharma Marketing Management 111

Pharmaceutical Technology

JUNE 29, 2022

For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. Meanwhile, the pharma industry is undergoing somewhat of a transformation itself. That is a key competitive advantage,” says Laursen. “We

Specialization 118

Specialization Biopharma B2B Sales Manufacturing 118

Clarivate

MAY 14, 2024

With only two3 GLP-1 drugs currently approved for weight loss—Huadong Medicine’s version of daily dosed liraglutide and thrice-a-day dosed beinaglutide from Benamae Pharma—the gap is substantial and leaves a solid market opportunity for weight loss drugs. What’s leading to the boom in development of semaglutide biosimilars?

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

pharmaphorum

JANUARY 27, 2023

While global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines. There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.”

Pharma 52

Pharma Manufacturing Biopharma Medicine 52

Clarivate

JULY 5, 2023

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. In 2022, it made its manufacturer, AbbVie, $21.2bn. This strategy is often chosen by the brand manufacturers who offer higher rebates at the net price level in exchange for better placement on formularies. The current U.S.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Clarivate

OCTOBER 25, 2023

What the addition of Part B may bring With the expansion of price negotiations to include Part B drugs in 2028 , Medicare reimbursement may become challenging for additional manufacturers. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

AUGUST 22, 2022

percent of biopharmaceutical companies outsource at least some of their activities, which has helped make biopharmaceutical contract manufacturing a $14 billion industry. The investigators foresee a highly promising and profitable future for biopharmaceutical contract development and manufacturing organisations (CDMOs) over the next decade.

Biopharma 79

Biopharma Manufacturing Marketing Competition 79

European Pharmaceutical Review

DECEMBER 19, 2022

Furthermore, the joint statement cites examples of successful switch of biological medicines manufactured and commercialised by different companies, which is stated to have become “common in clinical practice”. The Impact of Biosimilar Competition in Europe, IQVIA, December 2021. EMA Biosimilars Q&A. Lausuntopalvelu.fi.

Medicine 52

Medicine Biopharma Safety Food 52

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

PM360

SEPTEMBER 28, 2022

Now, as the President of Accord BioPharma , the U.S. PM360: From your time at Roche when you were dealing with biosimilars as potential competition to now leading the launch of biosimilars at Accord and Intas, how have you seen the marketplace for biosimilars evolve over that time? specialty division of Intas Pharmaceuticals, Ltd.,

Competition 98

Competition Marketing Biopharma Manufacturing 98

Clarivate

MAY 24, 2023

With 11 gene therapies already approved payers are bracing for impact as Cortellis Competitive Intelligence data identifies another 30 in late-stage pipelines. For payers, however, the vote in favor of Sarepta Therapeutics’ SRP-9001 added urgency to the task of shoring up value assessment and utilization management practices.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Pharmaceutical Technology

MARCH 21, 2023

In such turbulent times, ensuring the most efficient and cost-effective manufacturing frameworks becomes even more important. Most pharmaceutical and biotech companies outsource certain production tasks to contract manufacturing organizations (CMOs). SK Biotek is contracted to manufacture the small molecule API.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59

Pharmaceutical Technology

JANUARY 15, 2023

In order to get a therapy to the market, pharma companies often outsource the drug manufacturing to specialist contract manufacturing organizations (CMOs). While Catalent Inc and PCI Pharma Services are in charge of the solid dose and packaging of Lupkynis, Lonza is manufacturing the small molecule API.

Manufacturing 52

Manufacturing Pharmaceutical FDA Pharma 52

Pharmaceutical Technology

MARCH 24, 2023

GC Biopharma is also running a Phase III trial for its live-attenuated vaccine GC-3107A to replace BCG. Accounting for the time needed to complete the trial, publish results and manufacture the vaccine, if successful, market access to TB vaccines may be 10 years away.

Pharma 64

Pharma Side effects Marketing Biopharma 64

Pharmaceutical Technology

FEBRUARY 27, 2023

Manufacturing a drug therapy usually involves several different stakeholders. Baxter Biopharma Solutions has been contracted for the ADC’s parenteral manufacture and packaging. Regulatory decisions by the EMA for select therapies from late December to late January, and the CMOs contracted to manufacture them.

Manufacturing 52

Manufacturing Pharmaceutical Pharma FDA 52

Pharmaceutical Technology

APRIL 16, 2023

The question now is how to best design and manufacture autoinjectors that can be used to safely store and administer these larger volumes. Citeline Pharma Intelligence report – Pharma R&D Annual Review 2022: Navivating the Landscape 2. The challenge with prefilled syringes Most autoinjectors have fill volumes of 1.0

Medical 52

Medical Medicine Patients Manufacturing 52